CRISPR Therapeutics (CRSP) highlighted its strategic priorities and anticipated 2025 milestones. Key Priorities: Ongoing launch of CASGEVY, driven by strong patient demand and robust payer and system support. Continue advancing pipeline candidates, with several key updates in 2025, including CTX112 in oncology and autoimmune diseases, as well as CTX310 and CTX320 in cardiovascular indications, alongside the potential for further updates across our pipeline. Continue advancing next-generation gene editing and lipid nanoparticle delivery platform for the liver, hematopoietic stem cells, and other target organs. CRISPR Therapeutics anticipates several key milestones in 2025 across its development portfolio: Quarterly updates on CASGEVY launch progress; Updates for CTX310 and CTX320 in the first half of 2025; A broad update with CTX112 in oncology and autoimmune disease in mid-2025; Update for CTX131 in 2025; Update in regenerative medicine in 2025
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRSP:
- Crispr Therapeutics proposes to elect Briggs Morrison to board
- Crispr Therapeutics price target lowered to $85 from $98 at BofA
- Crispr Therapeutics call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment bought 58K shares of Crispr Therapeutics today
- Crispr Therapeutics presents data on CTX112 at ASH Meeting
Questions or Comments about the article? Write to editor@tipranks.com